Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
  2. >
  3. Stock
  4. >
  5. EXAS
stocks logo

EXAS

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
774.35M
+10.74%
0.066
-213.77%
796.69M
+12.42%
0.143
-212.01%
820.79M
+15.05%
0.203
-437.78%
Estimates Revision
The market is revising Upward the revenue expectations for Exact Sciences Corporation (EXAS) for FY2025, with the revenue forecasts being adjusted by 1.35% over the past three months. During the same period, the stock price has changed by 12.59%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.35%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-21.73%
In Past 3 Month
Stock Price
Go Up
up Image
+12.59%
In Past 3 Month
19 Analyst Rating
up Image0
Wall Street analysts forecast EXAS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXAS is 69.94 USD with a low forecast of 54.00 USD and a high forecast of 90.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Buy
1 Hold
0 Sell
Strong Buy
up Image0
Current: 53.020
sliders
Low
54.00
Averages
69.94
High
90.00
up Image0
Current: 53.020
sliders
Low
54.00
Averages
69.94
High
90.00
Guggenheim
Subbu Nambi
Strong Buy
Reiterates
$60
2025-04-11
Reason
Guggenheim
Subbu Nambi
Price Target
$60
2025-04-11
Reiterates
Strong Buy
Reason
Barclays
Luke Sergott
Buy
Maintains
$65 → $55
2025-04-10
Reason
Barclays
Luke Sergott
Price Target
$65 → $55
2025-04-10
Maintains
Buy
Reason
Barclays analyst Luke Sergott lowered the firm's price target on Exact Sciences to $55 from $65 and keeps an Overweight rating on the shares as part of a Q1 earnings preview for life science tools and diagnostics group. Tools are still defensive, but less so than in the past given the threat of the pharma-specific tariffs potentially causing another round of budget cuts, the analyst tells investors in a research note. Barclays also downgraded the contract research organizations on lower visibility.
Mizuho
Anthony Petrone
Buy
Initiates
$60
2025-04-10
Reason
Mizuho
Anthony Petrone
Price Target
$60
2025-04-10
Initiates
Buy
Reason
Mizuho initiated coverage of Exact Sciences with an Outperform rating and $60 price target.
RBC Capital
Gerard Cassidy
Hold
Initiates
$52
2025-03-13
Reason
RBC Capital
Gerard Cassidy
Price Target
$52
2025-03-13
Initiates
Hold
Reason
RBC Capital initiated coverage of Exact Sciences with a Sector Perform rating and $52 price target while launching coverage of the Liquid Biopsy space. Exact is the leader in colorectal cancer with its at-home test, Cologuard, the analyst noted. While it has had success displacing traditional screening methods for CRC, new competitive entrants are likely to dampen Exact's growth going forward and the stool-based testing method does not transfer over to other areas of cancer testing so the firm contends that it is unclear if the company will have success with its upcoming product launches.
Piper Sandler
David Westenberg
Buy
Maintains
$75 → $70
2025-02-26
Reason
Piper Sandler
David Westenberg
Price Target
$75 → $70
2025-02-26
Maintains
Buy
Reason
Piper Sandler lowered the firm's price target on Exact Sciences to $70 from $75 following quarterly results. The firm keeps an Overweight rating on the shares.
Scotiabank
Sung Ji Nam
Buy
Maintains
$70 → $73
2025-02-24
Reason
Scotiabank
Sung Ji Nam
Price Target
$70 → $73
2025-02-24
Maintains
Buy
Reason
Scotiabank raised the firm's price target on Exact Sciences to $73 from $70 and keeps an Outperform rating on the shares. Exact's Q4 was in line with the January 12 preannouncement, and the company ended FY24 slightly below initial guide provided last year, the analyst tells investors in a research note. The firm thinks Exact is strongly positioned competitively, based on clinical data presented so far, as well as its extensive commercial channels leveraging ExactNexus.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Exact Sciences Corp (EXAS.O) is 103.11, compared to its 5-year average forward P/E of -69.10. For a more detailed relative valuation and DCF analysis to assess Exact Sciences Corp 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-69.10
Current PE
103.11
Overvalued PE
47.94
Undervalued PE
-186.14

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
6.28
Current EV/EBITDA
25.30
Overvalued EV/EBITDA
124.26
Undervalued EV/EBITDA
-111.69

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
6.04
Current PS
3.23
Overvalued PS
9.14
Undervalued PS
2.94

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 614.09% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

EXAS News & Events

Events Timeline

(ET)
2025-05-28
06:09:45
Exact Sciences to present new positive data on Oncodetect in colorectal cancer
select
2025-05-01 (ET)
2025-05-01
16:15:31
Exact Sciences raises FY25 revenue view to $3.07B-$3.12B, consensus $3.06B
select
2025-05-01
16:14:40
Exact Sciences reports Q1 EPS (54c) vs (60c) last year
select
Sign Up For More Events
Sign Up For More Events

News

Preview
5.0
06-17NASDAQ.COM
Insider Sale: Director at $EXAS Sells 3,207 Shares
  • Insider Trading Activity: Katherine S Zanotti, a director at $EXAS, sold 3,207 shares for approximately $170,612, reducing her holdings to 72,759 shares. In the past six months, there has been one insider sale and no purchases of $EXAS stock.

  • Institutional and Analyst Insights: 240 institutional investors increased their positions in $EXAS while 373 decreased theirs. Analysts have issued two buy ratings and set a median price target of $65.0 for the stock in recent months.

Preview
2.0
06-10NASDAQ.COM
EXACT Sciences (EXAS) Shares Cross Above 200 DMA
  • Stock Performance Overview: EXAS has a 52-week low of $39.97 and a high of $72.83, with the last trade recorded at $56.34.

  • Author's Perspective: The opinions expressed in the article are solely those of the author and do not necessarily represent Nasdaq, Inc.

Preview
4.5
06-09NASDAQ.COM
Noteworthy ETF Inflows: XBI, EXAS, NBIX, NTRA
  • XBI Share Price Analysis: The XBI ETF has a 52-week low of $66.66 and a high of $105.47, with the latest trade at $84.09, indicating its current position within this range.

  • ETF Trading Dynamics: ETFs function like stocks but involve trading "units" that can be created or destroyed based on investor demand, affecting the underlying holdings and market flows.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Exact Sciences Corp (EXAS) stock price today?

The current price of EXAS is 53.02 USD — it has increased 1.3 % in the last trading day.

arrow icon

What is Exact Sciences Corp (EXAS)'s business?

Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

arrow icon

What is the price predicton of EXAS Stock?

Wall Street analysts forecast EXAS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXAS is 69.94 USD with a low forecast of 54.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Exact Sciences Corp (EXAS)'s revenue for the last quarter?

Exact Sciences Corp revenue for the last quarter amounts to 706.79M USD, increased 10.86 % YoY.

arrow icon

What is Exact Sciences Corp (EXAS)'s earnings per share (EPS) for the last quarter?

Exact Sciences Corp. EPS for the last quarter amounts to -0.54 USD, decreased -10.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Exact Sciences Corp (EXAS)'s fundamentals?

The market is revising Upward the revenue expectations for Exact Sciences Corporation (EXAS) for FY2025, with the revenue forecasts being adjusted by 1.35% over the past three months. During the same period, the stock price has changed by 12.59%.
arrow icon

How many employees does Exact Sciences Corp (EXAS). have?

Exact Sciences Corp (EXAS) has 6900 emplpoyees as of June 23 2025.

arrow icon

What is Exact Sciences Corp (EXAS) market cap?

Today EXAS has the market capitalization of 10.00B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free